Mutations in the TP53 gene show features of somatic hypermutation process with prominent difference between IGHV mutated and unmutated chronic lymphocytic leukemia.

TOM, Nikola, Jitka MALČÍKOVÁ, Lenka RADOVÁ, Barbara KANTOROVÁ, Filip PARDY, Šárka PAVLOVÁ, Karol PÁL, Vasileios BIKOS, Boris TICHÝ, Michael DOUBEK, Yvona BRYCHTOVÁ, Karla PLEVOVÁ, Jiří MAYER, Martin TRBUŠEK and Šárka POSPÍŠILOVÁ. Mutations in the TP53 gene show features of somatic hypermutation process with prominent difference between IGHV mutated and unmutated chronic lymphocytic leukemia. In International Workshop Algorithmics, Bioinformatics and Statistics for NGS data analysis. 2015.

Basic information

• Original name: Mutations in the TP53 gene show features of somatic hypermutation process with prominent difference between IGHV mutated and unmutated chronic lymphocytic leukemia.
• Authors: TOM, Nikola, Jitka MALČÍKOVÁ, Lenka RADOVÁ, Barbara KANTOROVÁ, Filip PARDY, Šárka PAVLOVÁ, Karol PÁL, Vasileios BIKOS, Boris TICHÝ, Michael DOUBEK, Yvona BRYCHTOVÁ, Karla PLEVOVÁ, Jiří MAYER, Martin TRBUŠEK and Šárka POSPÍŠILOVÁ.
• Edition: International Workshop Algorithmics, Bioinformatics and Statistics for NGS data analysis, 2015.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• ED1.1.00/02.0068, research and development project: Name: CEITEC - central european institute of technology
• MUNI/A/1180/2014, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit II (Acronym: VýDiTeHeMa II)

Investor: Masaryk University, Category A

• NT11218, research and development project: Name: Funkční a strukturní změny microRNA u lymfoproliferativních malignit a jejich vliv na prognózu onemocnění a predikci léčebné odpovědi
• NT13493, research and development project: Name: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
• NT13519, research and development project: Name: Časná identifikace CLL pacientů s dosud nevyselektovanými mutacemi v proteinu p53
• 306242, interní kód MU: Name: NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)

Investor: European Union, Cooperation